Aseptic meningitis: a rare side effect of cetuximab therapy.
Cetuximab, a chimeric IgG1 monoclonal antibody against the epidermal growth factor receptor, is indicated for the treatment of epidermal growth factor receptor-expressing metastatic colorectal cancer and recurrent or metastatic squamous cell cancer of the head and neck after failure of platinum-based therapy. The commonly reported side effects of cetuximab are infusion-related reactions, skin rash, fatigue, malaise and nausea. We report a case of aseptic meningitis developing as a rare side effect in a patient of stage IVB squamous maxillary cancer treated with cetuximab. To our knowledge, there have been very few cases of cetuximab-induced aseptic meningitis reported in literature. Clinicians should recognize that self-limiting aseptic meningitis can occur with administration of cetuximab. Our case report may serve as an additional reference for clinicians encountered with aseptic meningitis in the setting of using cetuximab.
['Emani|M K|MK|', 'Zaiden|R A|RA|']
D061067:Antibodies, Monoclonal, Humanized D000970:Antineoplastic Agents D002294:Carcinoma, Squamous Cell D000068818:Cetuximab D005260:Female D006801:Humans D008441:Maxillary Neoplasms D008582:Meningitis, Aseptic D008875:Middle Aged D009367:Neoplasm Staging
aseptic meningitis cetuximab Cetuximab-induced aseptic meningitis drug-induced aseptic meningitis side effects cetuximab